In estrogen receptor-positive breast cancer, prostate cancer [14], acute myeloid leukemia, and thyroid carcinoma [6], FOXA1 exhibits a potential cancer-promoting effect; however, it causes tumor inhibition in estrogen receptor-negative breast cancer [15], advanced prostate cancer, and pancreatic cancer [10]. This evidence concerns the gene ESR1 and thyroid gland carcinoma.